Xeris Biopharma Revised FY24 Total Revenue Outlook To $190M-$200M (From $175M-$200M) Vs. $187.349M Estimate
Portfolio Pulse from Benzinga Newsdesk
Xeris Biopharma has revised its FY24 total revenue outlook to a range of $190M-$200M, up from the previous range of $175M-$200M. This new outlook is above the $187.349M estimate.
August 08, 2024 | 11:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Xeris Biopharma has increased its FY24 revenue outlook to $190M-$200M, which is higher than the previous range and above the $187.349M estimate.
The upward revision of the revenue outlook indicates stronger than expected performance, which is likely to positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100